These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 34669521)

  • 1. New therapeutic targets and biomarkers for acute graft-versus-host disease (GVHD).
    Choe H; Ferrara JLM
    Expert Opin Ther Targets; 2021 Sep; 25(9):761-771. PubMed ID: 34669521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic targets and emerging treatment options in gastrointestinal acute graft-versus-host disease.
    Renteria AS; Levine JE; Ferrara JLM
    Expert Opin Orphan Drugs; 2016; 4(5):469-484. PubMed ID: 30057862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mesenchymal stromal cells as treatment or prophylaxis for acute or chronic graft-versus-host disease in haematopoietic stem cell transplant (HSCT) recipients with a haematological condition.
    Fisher SA; Cutler A; Doree C; Brunskill SJ; Stanworth SJ; Navarrete C; Girdlestone J
    Cochrane Database Syst Rev; 2019 Jan; 1(1):CD009768. PubMed ID: 30697701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current and Emerging Targeted Therapies for Acute Graft-Versus-Host Disease.
    Kasikis S; Etra A; Levine JE
    BioDrugs; 2021 Jan; 35(1):19-33. PubMed ID: 33201499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of Elafin as a Prognostic Biomarker in Acute Graft-versus-Host Disease.
    Zewde MG; Morales G; Gandhi I; Özbek U; Aguayo-Hiraldo P; Ayuk F; Baez J; Chanswangphuwana C; Choe H; DeFilipp Z; Etra A; Grupp S; Hexner EO; Hogan W; Javorniczky NR; Kasikis S; Kitko CL; Kowalyk S; Meedt E; Merli P; Nakamura R; Qayed M; Reshef R; Rösler W; Schechter T; Weber D; Wölfl M; Yanik G; Young R; Levine JE; Ferrara JLM; Chen YB
    Transplant Cell Ther; 2021 Dec; 27(12):988.e1-988.e7. PubMed ID: 34474163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628).
    von Bubnoff N; Ihorst G; Grishina O; Röthling N; Bertz H; Duyster J; Finke J; Zeiser R
    BMC Cancer; 2018 Nov; 18(1):1132. PubMed ID: 30453910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polyclonal anti-thymocyte globulins for the prophylaxis of graft-versus-host disease after allogeneic stem cell or bone marrow transplantation in adults.
    Theurich S; Fischmann H; Shimabukuro-Vornhagen A; Chemnitz JM; Holtick U; Scheid C; Skoetz N; von Bergwelt-Baildon M
    Cochrane Database Syst Rev; 2012 Sep; (9):CD009159. PubMed ID: 22972135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MAGIC biomarkers of acute graft-versus-host disease: Biology and clinical application.
    Srinagesh HK; Ferrara JLM
    Best Pract Res Clin Haematol; 2019 Dec; 32(4):101111. PubMed ID: 31779977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mycophenolate mofetil versus methotrexate for prevention of graft-versus-host disease in people receiving allogeneic hematopoietic stem cell transplantation.
    Kharfan-Dabaja M; Mhaskar R; Reljic T; Pidala J; Perkins JB; Djulbegovic B; Kumar A
    Cochrane Database Syst Rev; 2014 Jul; 2014(7):CD010280. PubMed ID: 25061777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. α4β7 Integrin expression and blockade in pediatric and young adult gastrointestinal graft-versus-host disease.
    Ibrahimova A; Davies SM; Lane A; Jordan MB; Lake K; Litts B; Chaturvedi V; Owsley E; Myers KC; Nelson AS; Mehta PA; Marsh RA; Khandelwal P
    Pediatr Blood Cancer; 2021 Aug; 68(8):e28968. PubMed ID: 33861521
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems.
    MacMillan ML; Weisdorf DJ; Wagner JE; DeFor TE; Burns LJ; Ramsay NK; Davies SM; Blazar BR
    Biol Blood Marrow Transplant; 2002; 8(7):387-94. PubMed ID: 12171485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biomarker-guided preemption of steroid-refractory graft-versus-host disease with α-1-antitrypsin.
    Gergoudis SC; DeFilipp Z; Özbek U; Sandhu KS; Etra AM; Choe HK; Kitko CL; Ayuk F; Aziz M; Baez J; Ben-David K; Bunworasate U; Gandhi I; Hexner EO; Hogan WJ; Holler E; Kasikis S; Kowalyk SM; Lin JY; Merli P; Morales G; Nakamura R; Reshef R; Rösler W; Srinagesh H; Young R; Chen YB; Ferrara JLM; Levine JE
    Blood Adv; 2020 Dec; 4(24):6098-6105. PubMed ID: 33351103
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ruxolitinib-corticosteroid as first-line therapy for newly diagnosed high-risk acute graft versus host disease: study protocol for a multicenter, randomized, phase II controlled trial.
    Dou L; Peng B; Li X; Wang L; Jia M; Xu L; Li F; Liu D
    Trials; 2022 Jun; 23(1):470. PubMed ID: 35668528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extracorporeal photophoresis: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2006; 6(6):1-82. PubMed ID: 23074497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Steroid-Sensitive, but Not Steroid-Dependent or Steroid-Resistant Acute Graft-versus-Host Disease, Results in Similar Infection Risk as No Graft-versus-Host Disease following Allogeneic Hematopoietic Cell Transplantation.
    Young JH; El Jurdi N; Rayes A; MacMillan ML; Holtan SG; Cao Q; Witte J; Arora M; Weisdorf DJ
    Transplant Cell Ther; 2022 Aug; 28(8):509.e1-509.e11. PubMed ID: 35577324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute Steroid-Refractory Gastrointestinal Graft-Versus-Host Disease Is Not Associated With Significant Differences in Gut Taxonomic Composition Compared to Steroid-Sensitive Gastrointestinal Graft-Versus-Host Disease Immediately Before Onset of Disease.
    Zeng K; Brewster R; Kang JB; Tkachenko E; Brooks E; Bhatt AS; Fodor AA; Andermann TM
    Transplant Cell Ther; 2024 Feb; 30(2):237.e1-237.e9. PubMed ID: 37944820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel therapies for graft versus host disease with a focus on cell therapies.
    Zeiser R; Ringden O; Sadeghi B; Gonen-Yaacovi G; Segurado OG
    Front Immunol; 2023; 14():1241068. PubMed ID: 37868964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Janus kinase inhibition in the treatment and prevention of graft-versus-host disease.
    De Togni E; Cole O; Abboud R
    Front Immunol; 2024; 15():1304065. PubMed ID: 38380328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of mesenchymal stromal cell therapy for multi-drug-resistant acute and late-acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.
    Keklik M; Deveci B; Celik S; Deniz K; Gonen ZB; Zararsiz G; Saba R; Akyol G; Ozkul Y; Kaynar L; Keklik E; Unal A; Cetin M; Jones OY
    Ann Hematol; 2023 Jun; 102(6):1537-1547. PubMed ID: 37067556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.